WuXi Biologics (Cayman) Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- WuXi Biologics (Cayman) Inc. operates as a premier global Contract Research, Development and Manufacturing Organization (CRDMO), delivering comprehensive, integrated solutions for the entire biologics lifecycle, from initial discovery to commercial production. The company's extensive service portfolio spans drug substance and drug product development and manufacturing for a wide array of biopharmaceuticals, including monoclonal antibodies, bispecifics, fusion proteins, and vaccines. Additionally, through its WuXi XDC segment, it offers specialized services for antibody-drug conjugates (ADCs) and other bioconjugates. WuXi Biologics maintains a significant international footprint with operational facilities and research centers located across China, the United States, Ireland, Germany, and Singapore, enabling efficient global support for its clientele. The firm actively engages in strategic alliances, recently partnering with Virogen Biotechnology for commercial manufacturing and collaborating with OncoC4 for exclusive CDMO services, leveraging its proprietary technology platforms. Formed in 2014, the company is headquartered in Wuxi, China.
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
WuXi Biologics (Cayman) Inc. (WXXWY) Q4 2025 Earnings Call Transcript
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
WuXi Biologics Reports Record 2025 Annual Results
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally